London — It will probably be at least 10 years before any new generation of antidepressants comes to market, despite evidence that depression and anxiety rates are rising worldwide, say specialists. The depression drug pipeline has run dry due to "failure of science" and big pharma groups pulling investment out of research and development in the neuroscience field because of uncertainty on profit potential, they say. "I’d be very surprised if we were to see any new drugs for depression in the next decade. The pharmaceutical industry is simply not investing in the research because it can’t make money from these drugs," Guy Goodwin, a professor of psychiatry at the University of Oxford, told reporters in London. Andrea Cipriani, a consultant psychiatrist at Oxford, said risk aversion was understandable, given uncertain returns and the cost of developing and bringing a new drug to market at about $1bn. "It’s a lot of money to spend, and there’s a high rate of failure," Cipriani said. T...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now